Examkin

Question

Difficulty: Very hardGynecologic Oncology

A 59-year-old woman is evaluated in the gynecology clinic for a persistent, clear vaginal discharge over the past three months. She has not experienced any vaginal bleeding. Menopause occurred 8 years ago. Her past medical history is significant for type 2 diabetes mellitus and a body mass index of 37 kg/m². Current medications include metformin and lisinopril. On speculum examination, the vaginal mucosa appears pale and thin, and the cervix has no visible lesions or bleeding. Bimanual examination reveals a small, mobile uterus and no adnexal masses. A cervical cytology specimen is collected, which subsequently returns positive for atypical glandular cells. To further investigate, the physician performs a transvaginal ultrasound in the office, which demonstrates normal-sized ovaries and an endometrial stripe measuring 3 mm in thickness. Based on these findings, which of the following is the most appropriate next step in the patient's management?

  1. Colposcopy with endocervical curettage and endometrial biopsyAnswer
  2. B
    Colposcopy with endocervical curettage only
  3. C
    Endometrial biopsy only
  4. D
    Diagnostic excisional procedure of the cervix
  5. E
    Repeat cervical cytology and human papillomavirus testing in 6 months

Answer

Colposcopy with endocervical curettage and endometrial biopsy
The correct management for this patient is colposcopy with endocervical curettage and endometrial biopsy. Atypical glandular cells (AGC) on cervical cytology can originate from the cervix, endometrium, or occasionally the fallopian tubes or ovaries. In women age 35 and older, or in younger women with risk factors for endometrial cancer (e.g., obesity, diabetes, chronic anovulation), clinical guidelines mandate comprehensive evaluation of both the cervix and the endometrium. This consists of colposcopy, endocervical sampling, and endometrial biopsy. A common and dangerous pitfall is attempting to use transvaginal ultrasound to triage these patients. While a transvaginal ultrasound endometrial stripe of 4 mm or less is highly reassuring in the setting of isolated postmenopausal bleeding, it is not an acceptable substitute for histologic sampling in patients with AGC. The finding of a 3 mm stripe in this patient does not eliminate the requirement for an endometrial biopsy.

Step-by-Step Solution

1
Identify the primary abnormal finding in the clinical vignette.
The patient has atypical glandular cells (AGC) on a routine Papanicolaou test.
AGC is a high-risk cytology result that is managed differently than atypical squamous cells, given its strong association with cervical, endometrial, and adnexal adenocarcinomas.
2
Evaluate patient demographics and risk factors relevant to the abnormal cytology.
The patient is 59 years old, postmenopausal, obese, and diabetic, placing her at high risk for endometrial hyperplasia and carcinoma.
Current guidelines stratify AGC management based on an age cutoff of 35 years and the presence of endometrial cancer risk factors.
3
Determine the mandatory diagnostic modalities for this demographic presenting with AGC.
Comprehensive sampling of the cervix (colposcopy and endocervical curettage) and the endometrium (endometrial biopsy) is required.
Atypical glandular cells can originate from the endocervix or the endometrium; therefore, both anatomical sites must be histologically evaluated simultaneously.
4
Assess the impact of the transvaginal ultrasound finding on the management algorithm.
The 3 mm endometrial stripe does not alter the management plan; the endometrial biopsy remains mandatory.
While a thin endometrial stripe is reassuring in isolated postmenopausal bleeding, it is not an acceptable triage tool for AGC, as endometrial cancers presenting with AGC may not uniformly thicken the endometrium.

Key Concept

In women age 35 and older, or those with risk factors for endometrial cancer, the finding of atypical glandular cells (AGC) on cervical cytology mandates colposcopy, endocervical curettage, and endometrial biopsy, regardless of transvaginal ultrasound findings.
Rate this question

Topics

Gynecologic Oncology

More questions from this topic